المؤلفون: A. F. Verbovoy, N. I. Verbovaya, Yu. A. Dolgikh

المصدر: Ожирение и метаболизм, Vol 18, Iss 2, Pp 142-149 (2021)

مصطلحات موضوعية: metabolic syndrome, obesity, leptin, adiponectin, resistin, apelin, Physiology, QP1-981, Biochemistry, QD415-436

وصف الملف: electronic resource

العلاقة: https://www.omet-endojournals.ru/jour/article/view/12707Test; https://doaj.org/toc/2071-8713Test; https://doaj.org/toc/2306-5524Test

الوصول الحر: https://doaj.org/article/d1612866db28443da936ac9c42c2060bTest

المؤلفون: A. F. Verbovoy, N. I. Verbovaya, Yu. A. Dolgikh

المصدر: Медицинский совет, Vol 0, Iss 14, Pp 80-89 (2020)

مصطلحات موضوعية: cardiovascular diseases, prediabetes, type 2 diabetes mellitus, thyroid diseases, adrenal diseases, acromegaly, Medicine

وصف الملف: electronic resource

العلاقة: https://www.med-sovet.pro/jour/article/view/5815Test; https://doaj.org/toc/2079-701XTest; https://doaj.org/toc/2658-5790Test

الوصول الحر: https://doaj.org/article/694a9509dc5841e08bb0ed0bec2abddfTest

المؤلفون: A. F. Verbovoy, N. I. Verbovaya, Yu. A. Dolgikh, А. Ф. Вербовой, Н. И. Вербовая, Ю. А. Долгих

المصدر: Meditsinskiy sovet = Medical Council; № 23 (2022); 199-204 ; Медицинский Совет; № 23 (2022); 199-204 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: глимепирид, hypoglycemic therapy, metformin, glibenclamide, glimepiride, сахароснижающая терапия, метформин, глибенкламид

وصف الملف: application/pdf

العلاقة: https://www.med-sovet.pro/jour/article/view/7327/6549Test; Дедов И.И., Шестакова М.В., Викулова О.К., Железнякова А.В., Исаков М.А. Эпидемиологические характеристики сахарного диабета в Российской Федерации: клинико-статистический анализ по данным регистра сахарного диабета на 01.01.2021. Сахарный диабет. 2021;24(3):204–221. https://doi.org/10.14341/DM12759Test.; Дедов И.И., Шестакова М.В., Майоров А.Ю. (ред.). Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 9-й выпуск. Сахарный диабет. 2019;22(Suppl. 1):1–144. https://doi.org/10.14341/DM221S1Test.; Викулова О.К., Железнякова А.В., Исаков М.А., Серков А.А., Шестакова М.В., Дедов И.И. Динамический анализ состояния углеводного обмена в субъектах Российской Федерации по данным мобильного медицинского центра (Диамодуль) и регистра сахарного диабета Российской Федерации. Сахарный диабет. 2020;23(2):104–112. https://doi.org/10.14341/DM12327Test.; Дедов И.И., Шестакова М.В., Майоров А.Ю., Шамхалова М.Ш., Сухарева О.Ю., Галстян Г.Р. и др. Сахарный диабет 2 типа у взрослых. Клинические рекомендации. Сахарный диабет. 2020;23(2 Suppl.):4–102. https://doi.org/10.14341/DM12507Test.; Shu A.D. Adherence to osteoporosis medication after patient and physician brief education: post hoc analysis of a randomized controller trial. Am J Manag Care. 2009;15(7):417–424. Available at: https://pubmed.ncbi.nlm.nih.gov/19589009Test.; Morris A.D. Considerations in assessing effectiveness and costs of diabetes care: lessons from DARTS. Diabetes Metab Res Rev. 2002;8(3):32–35. https://doi.org/10.1002/dmrr.295Test.; Rojas L.B., Gomes M.B. Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr. 2013;5(1):6. https://doi.org/10.1186/1758-5996-5-6Test.; Markowicz-Piasecka M., Huttunen K.M., Mateusiak L., Mikiciuk-Olasik E., Sikora J. Is Metformin a Perfect Drug? Updates in Pharmacokinetics and Pharmacodynamics. Curr Pharm Des. 2017;23(17):2532–2550. https://doi.org/10.2174/1381612822666161201152941Test.; Rena G., Hardie G.G., Pearson E.A. The mechanisms of action of metformin. Diabetologia. 2017;60(9):1577–1585. https://doi.org/10.1007/s00125-017-4342-zTest.; Вербовой А.Ф., Вербовая Н.И., Ломонова Т.В., Долгих Ю.А. Метформин – время расширять показания? РМЖ. 2021;(2):37–41. Режим доступа: https://www.rmj.ru/articles/endokrinologiya/Metformin_vremya_rasshiryaty_pokazaniya/#ixzz7HyWgr6AVTest.; Древаль А.В., Мисникова И.В., Триголосова И.В., Тишенина Р.С. Влияние метформина на углеводный и липидный обмен у лиц с ранними нарушениями углеводного обмена. Сахарный диабет. 2010;13(2):63–67. https://doi.org/10.14341/2072-0351-5676Test.; Effect of intensive blood-glucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):854–865. Available at: https://pubmed.ncbi.nlm.nih.gov/9742977Test.; Scarpello J.H. Improving survival with metformin: the evidence base today. Diabetes Metab. 2003;29(4):636–643. https://doi.org/10.1016/s1262-3636Test(03)72786-4.; McFarlane S.I., Banerij M., Sowers J.R. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab. 2001;86:713–718. https://doi.org/10.1210/jcem.86.2.7202Test.; Davidson M.B., Peters A.L. An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med. 1997;102(1):99–110. https://doi.org/10.1016/s0002-9343Test(96)00353-1.; Phung O.J., Sobieraj D.M., Engel S.S., Rajpathak S.N. Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and metaanalysis. Diabetes Obes Metab. 2014;16(5):410–417. https://doi.org/10.1111/dom.12233Test.; Zhang Y., McCoy R.G., Mason J.E., Smith S.A., Shah N.D., Denton B.T. et al. Second-line agents for glycemic control for type 2 diabetes: are newer agents better? Diabetes Care. 2014;37(5):1338–1345. https://doi.org/10.2337/dc13-1901Test.; Blonde L., Wogen J., Kreilick C., Seymour A.A. Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide-metformin tablets as compared to glyburide co-administered with metformin. Diabetes Obes Metab. 2003;5(6):424–431. https://doi.org/10.1046/j.1463-1326.2003.00297.xTest.; Duckworth W., Marcelli M., Padden M. et al. Improvements in glycemic control in type 2 diabetes patients switched from sulfonylurea coadministered with metformin to glyburide-metformin tablets. J Manag Care Pharm. 2003;9(3):256–262. https://doi.org/10.18553/jmcp.2003.9.3.256Test.; Lim P.C., Lim S.L., Oiyammaal C. Glycaemic control and cost analysis when changing from gliclazide co-administered with metformin to pre-combined glibenclamide-metformin tablets in type 2 diabetes mellitus. Med J Malaysia. 2012;67(1):21–24. Available at: https://pubmed.ncbi.nlm.nih.gov/22582544Test.; Cheong C., Barner J.C., Lawson K.A., Johnsrud M.T. Patient adherence and reimbursement amount for antidiabetic fixed dose combination products compared with dual therapy among texas medicaid recipients. Clin Ther. 2008;30(10):1893–1907. https://doi.org/10.1016/j.clinthera.2008.10.003Test.; Charpentier G., Fleury F., Kabir M., Vaur L., Halimi S. Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabetic Medicine. 2001;18(10):828–834. https://doi.org/10.1046/j.1464-5491.2001.00582.xTest.; Müller G., Hartz D., Pünter J., Okonomopulos R., Kramer W. Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. I. Binding characteristics. Biochimica et Biophysica Acta. 1994;1191(2):267–277. https://doi.org/10.1016/0005-2736Test(94)90177-5.; Shukla U.A., Chi E.M., Lehr K.H. Glimepiride pharmacokinetics in obese versus non-obese diabetic patients. Annals of Pharmacotherapy. 2004;38(1):30–35. https://doi.org/10.1345/aph.1C397Test.; Matsuki M., Matsuda M., Kohara K., Shimoda M., Kanda Y., Tawaramoto K. et al. Pharmacokinetics and pharmacodynamics of glimepiride in type 2 diabetic patients: compared effects of onceversus twice-daily dosing. Endocrine Journal. 2007;54(4):571–576. https://doi.org/10.1507/endocrj.k06-052Test.; Rosenkranz B., Profozic V., Metelko Z., Mrzljak V., Lange C., Malerczyk V. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia. 1996;39(12):1617–1624. https://doi.org/10.1007/s001250050624Test.; Pareek A., Chandurkar N.B., Salkar H.R., Borkar M.S., Tiwari D. Evaluation of efficacy and tolerability of glimepiride and metformin combination: a multicentric study in patients with type-2 diabetes mellitus, uncontrolled on monotherapy with sulfonylurea or metformin. Am J Ther. 2013;20(1):41–47. https://doi.org/10.1097/MJT.0b013e3181ff7c63Test.; González-Ortiz M., Guerrero-Romero J.F., Violante-Ortiz R., Wacher-Rodarte N., Martínez-Abundis E., Aguilar-Salinas C. et al. Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus. J Diabetes Complications. 2009;23(6):376–379. https://doi.org/10.1016/j.jdiacomp.2008.09.002Test.; Мкртумян А.М. Результаты наблюдательного исследования ESCALATION: особенности применения глимепирида у пациентов с сахарным диабетом 2-го типа, не достигших целевых показателей углеводного обмена на фоне терапии ингибитором ДПП-4 в комбинации с метформином. Проблемы эндокринологии. 2017;63(1):30–38. https://doi.org/10.14341/probl201763131-38Test.; Perkovic V., Heerspink H.L., Chalmers J., Woodward M., Jun M., Li Q. et al; ADVANCE Collaborative Group. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int. 2013;83(3):517–523. https://doi.org/10.1038/ki.2012.401Test.; ADVANCE Collaborative Group, Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M. et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572. https://doi.org/10.1056/NEJMoa0802987Test.; Oellgaard J., Gæde P., Rossing P., Persson F., Parving H.H., Pedersen O. Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits. Kidney Int. 2017;91(9):982–988. https://doi.org/10.1016/j.kint.2016.11.023Test.; Katakami N., Yamasaki Y., Hayashi-Okano R., Ohtoshi K., Kaneto H., Matsuhisa M. et al. Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. Diabetologia. 2004;47(11):1906–1913. https://doi.org/10.1007/s00125-004-1547-8Test.; Шестакова М.В., Викулова О.К. Результаты открытой наблюдательной программы DIAMOND. Сахарный диабет. 2011;14(3):96–102. https://doi.org/10.14341/2072-0351-6232Test.; Аметов А.С., Бутаева С.Г. Комбинированная сахароснижающая терапия: иДПП-4 в сравнении с сульфонилмочевиной. Эндокринологи: новости, мнения, обучение. 2018;7(1):76–81. https://doi.org/10.24411/2304-9529-2018-00008Test.; Zaccardi F., Jacquot E., Cortese V., Tyrer F., Seidu S., Davies M.J., Khunti K. Comparative effectiveness of gliclazide modified release versus sitagliptin as second-line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes. Diabetes, Obes Metab. 2020;22(12):2417–2426. https://doi.org/10.1111/dom.14169Test.; Maloney A., Rosenstock J., Fonseca V. A Model-Based Meta-Analysis of 24 Antihyperglycemic Drugs for Type 2 Diabetes: Comparison of Treatment Effects at Therapeutic Doses. Clin Pharmacol Ther. 2019;105(5):1213–1223. https://doi.org/10.1002/cpt.1307Test.; https://www.med-sovet.pro/jour/article/view/7327Test

الإتاحة: https://doi.org/10.21518/2079-701X-2022-16-23-199-204Test
https://doi.org/10.14341/DM12759Test
https://doi.org/10.14341/DM221S1Test
https://doi.org/10.14341/DM12327Test
https://doi.org/10.14341/DM12507Test
https://doi.org/10.1002/dmrr.295Test
https://doi.org/10.1186/1758-5996-5-6Test
https://doi.org/10.1007/s00125-017-4342-zTest
https://doi.org/10.14341/2072-0351-5676Test
https://doi.org/10.1016/s1262-3636Test(03)72786-4

المؤلفون: A F Verbovoy, A V Pashentseva, N I Verbovaya

المصدر: Терапевтический архив, Vol 91, Iss 10, Pp 139-143 (2019)

مصطلحات موضوعية: diabetes mellitus, diabetic macroangiopathy, coronary heart disease, obliterating atherosclerosis of arteries of the lower extremities, Medicine

العلاقة: https://ter-arkhiv.ru/0040-3660/article/viewFile/33722/pdfTest; https://doaj.org/toc/0040-3660Test; https://doaj.org/toc/2309-5342Test; https://doaj.org/article/4e624df113d44691b7ea5118bcd738b7Test

الإتاحة: https://doi.org/10.26442/00403660.2019.10.000109Test
https://doaj.org/article/4e624df113d44691b7ea5118bcd738b7Test

المؤلفون: A F Verbovoy, A V Pashentseva, N I Verbovaya, I V Madyanov, L A Sharonova, R A Galkin

المصدر: Терапевтический архив, Vol 90, Iss 8, Pp 113-117 (2018)

مصطلحات موضوعية: diabetes mellitus type 2, cardiovascular diseases, risk factors, treatment, Medicine

العلاقة: https://ter-arkhiv.ru/0040-3660/article/viewFile/32821/pdfTest; https://doaj.org/toc/0040-3660Test; https://doaj.org/toc/2309-5342Test; https://doaj.org/article/90cae14d796d47aaa8df949db8a665a3Test

الإتاحة: https://doi.org/10.26442/terarkh2018908113-117Test
https://doaj.org/article/90cae14d796d47aaa8df949db8a665a3Test

المؤلفون: N. I. Verbovaya, Yu.A. Dolgikh Dolgikh, A. F. Verbovoy

المصدر: Ожирение и метаболизм, Vol 18, Iss 2, Pp 142-149 (2021)

مصطلحات موضوعية: obesity, Physiology, Endocrinology, Diabetes and Metabolism, 030209 endocrinology & metabolism, QD415-436, 030204 cardiovascular system & hematology, Bioinformatics, leptin, Biochemistry, metabolic syndrome, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Internal Medicine, Medicine, QP1-981, resistin, Nutrition and Dietetics, adiponectin, business.industry, Public Health, Environmental and Occupational Health, medicine.disease, Obesity, apelin, Metabolic syndrome, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e60e2642b3c8ee43327ac80b14cab809Test
https://www.omet-endojournals.ru/jour/article/view/12707Test

المؤلفون: A F VERBOVOY, L A ShARONOVA, N I VERBOVAYa, D V AKIMOVA

المصدر: Остеопороз и остеопатии, Vol 17, Iss 1, Pp 8-10 (2014)

مصطلحات موضوعية: Osteopathy, RZ301-397.5

وصف الملف: electronic resource

العلاقة: https://endojournals.ru/index.php/osteo/article/view/8870Test; https://doaj.org/toc/2072-2680Test; https://doaj.org/toc/2311-0716Test

الوصول الحر: https://doaj.org/article/4c7db989062b41b19ed2fc28459cb6afTest

المؤلفون: A. F. Verbovoy, N. I. Verbovaya, L A Sharonova, R. A. Galkin, Yu.A. Dolgikh Dolgikh, A V Pashentseva

المصدر: Clinical Medicine (Russian Journal). 96:696-701

مصطلحات موضوعية: 03 medical and health sciences, medicine.medical_specialty, 0302 clinical medicine, business.industry, Internal medicine, Diabetes mellitus, medicine, 030209 endocrinology & metabolism, General Medicine, 030204 cardiovascular system & hematology, business, medicine.disease

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::15e0aca288e5fc09e44c3c38655b8a4eTest
https://doi.org/10.18821/0023-2149-2018-96-8-696-701Test

المؤلفون: N I Verbovaya, I V Madyanov, R. A. Galkin, A V Pashentseva, L A Sharonova, A F Verbovoy

المصدر: Терапевтический архив, Vol 90, Iss 8, Pp 113-117 (2018)

مصطلحات موضوعية: History, medicine.medical_specialty, diabetes mellitus type 2, Endocrinology, Diabetes and Metabolism, Cardiovascular risk factors, lcsh:Medicine, 030209 endocrinology & metabolism, 030204 cardiovascular system & hematology, 03 medical and health sciences, 0302 clinical medicine, Diabetes mellitus, medicine, Humans, risk factors, Mortality, Risk factor, Intensive care medicine, treatment, business.industry, lcsh:R, General Medicine, medicine.disease, cardiovascular diseases, Chronic disease, Diabetes Mellitus, Type 2, Approaches of management, Family Practice, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce832223bf03d761959a718f4358270bTest
https://ter-arkhiv.ru/0040-3660/article/viewFile/32821/pdfTest

المؤلفون: O V Kosareva, A Sharonova Lyudmila, Yu.A. Dolgikh Dolgikh, A. F. Verbovoy, N. I. Verbovaya

المصدر: Clinical Medicine (Russian Journal). 94:497-503

مصطلحات موضوعية: Vitamin, endocrine system, medicine.medical_specialty, endocrine system diseases, Adipokine, 030209 endocrinology & metabolism, Disease, 030204 cardiovascular system & hematology, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, medicine, Ventricular remodeling, Adiponectin, business.industry, Leptin, nutritional and metabolic diseases, General Medicine, medicine.disease, Endocrinology, chemistry, Resistin, business, hormones, hormone substitutes, and hormone antagonists, Dyslipidemia

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::5dbeab6c42991628197ebe101a011674Test
https://doi.org/10.18821/0023-2149-2016-94-7-497-503Test